cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-3-68-71cardiovascular-198Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMКОМБИНИРОВАННАЯ АНТИГИПЕРТЕНЗИВНАЯ ТЕРАПИЯ: КОГДА ЦЕЛОЕ БОЛЬШЕ СУММЫCOMBINATION ANTIHYPERTENSIVE THERAPY: WHEN THE WHOLE IS GREATER THAN THE SUM OF ITS PARTSТаратухинЕ. О.TaratukhinE. O.

кардиолог, к. м.н., ассистент кафедры госпитальной терапии № 1 лечебного факультета

Тел.: +7 916 637 29 78 

tel.: +7 916 637 29 78

cardio03@list.ruТепловаН. В.TeplovaN. V.

д. м.н., кардиолог, доцент кафедры

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава России, МоскваN. I. Pirogov Russian National Medical Research University, Moscow2013200620131236871Copyright © Таратухин Е.О., Теплова Н.В., 20132013Таратухин Е.О., Теплова Н.В.Taratukhin E.O., Teplova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/198

В статье поднимается вопрос об увеличении приверженности пациентов лечению при необходимости длительной или пожизненной терапии. Это осуществимо при применении комбинированных лекарственных препаратов, среди которых важна комбинация антагониста кальциевых каналов и ингибитора ангиотензин-превращающего фермента. Помимо более высокой комплаентности пациентов, комбинация позволяет пользоваться дополнительными метаболическими преимуществами, которыми обладают оба входящие в состав лекарственные средства. 

The paper discusses the importance of high treatment compliance in the case of long-term or life-long therapy. This problem can be resolved by the use of combination pharmacological treatment, such as the combination of a calcium channel blocker and an ACE inhibitor. Apart from the higher treatment compliance, this combination provides additional metabolic benefits, due to the beneficial metabolic effects of its components. 

ингибитор ангиотензин-превращающего ферментаблокатор кальциевых каналовпротивовоспалительныйантиатеросклеротическийнефропротективный эффектыинсулинорезистентностьACE inhibitorcalcium channel blockeranti-inflammatoryanti-atheroscleroticand nephroprotective effectsinsulin resistanceReferencesHoyer J. Non-pharmacological and pharmacological treatment of arterial hypertension: current situation. Herz 2012; 37 (7): 728–34.Hoyer J. Non-pharmacological and pharmacological treatment of arterial hypertension: current situation. Herz 2012; 37 (7): 728–34.Widimsky J. The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension. Vnitr Lek 2009; 55 (2): 123–30.Widimsky J. The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension. Vnitr Lek 2009; 55 (2): 123–30.Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol 2013; 32: 85–93.Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol 2013; 32: 85–93.Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.Sansanayudh N, Wongwiwatt S, Veerayuth S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 93: 84–92.Sansanayudh N, Wongwiwatt S, Veerayuth S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 93: 84–92.Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens 2013; 31 Suppl1: 9–12.Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens 2013; 31 Suppl1: 9–12.Krysiak R, Okopień B. Lymphocyte-suppressing action of angiotensin￾converting enzyme inhibitors in coronary artery disease patients with normal BP. Pharmacol Rep 2011; 63: 1151–61.Krysiak R, Okopień B. Lymphocyte-suppressing action of angiotensin￾converting enzyme inhibitors in coronary artery disease patients with normal BP. Pharmacol Rep 2011; 63: 1151–61.Chen JL, Shang QH, Hu W, et al. Role of TGF/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by enalapril and amlodipine. J Geriatr Cardiol 2012; 9: 185–91.Chen JL, Shang QH, Hu W, et al. Role of TGF/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by enalapril and amlodipine. J Geriatr Cardiol 2012; 9: 185–91.Hale TM, Robertson SJ, Burns KD, et al. Short-term ACE inhibition confers long-term protection against target organ damage. Hypertens Res 2012; 35: 604–10.Hale TM, Robertson SJ, Burns KD, et al. Short-term ACE inhibition confers long-term protection against target organ damage. Hypertens Res 2012; 35: 604–10.Velez Rueda JO, Palomeque J, Mattiazzi A, et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol 2012; 112: 2110–20.Velez Rueda JO, Palomeque J, Mattiazzi A, et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol 2012; 112: 2110–20.Purclutepe O, Iskender G, Kiper HD, et al. Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A. Anticancer Res 2012; 32: 2885–93.Purclutepe O, Iskender G, Kiper HD, et al. Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A. Anticancer Res 2012; 32: 2885–93.Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease. Int J Cardiol 2012; Jan 16.Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease. Int J Cardiol 2012; Jan 16.Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011; 13: 765–72.Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011; 13: 765–72.Shetty PK, Suthar NA, Menon J, et al. Transdermal delivery of lercanidipine hydrochloride. Curr Drug Deliv 2013; Jan 3.Shetty PK, Suthar NA, Menon J, et al. Transdermal delivery of lercanidipine hydrochloride. Curr Drug Deliv 2013; Jan 3.Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh 2012; 6: 449–55.Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh 2012; 6: 449–55.Bangalore S, Kamala G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.Bangalore S, Kamala G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.Messerli FH. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med 2008; 13: 18–22.Messerli FH. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med 2008; 13: 18–22.Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010; 55: 399–407.Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010; 55: 399–407.Cicero AF, Gerocarni B, Rosticci M, et al. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34 (2): 113–7.Cicero AF, Gerocarni B, Rosticci M, et al. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34 (2): 113–7.Egan CG, Pontremoli R. Role of th fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol 2011; 24 (4): 426–37.Egan CG, Pontremoli R. Role of th fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol 2011; 24 (4): 426–37.

The authors declare that there are no conflicts of interest present.